0.640
0.000
(0.00%)
May 21 - Close
NYSEMKT
real-time data -
Disclaimer
Currency in USD
| Range | 0.63 - 0.65 |
| 52 week | 0.40 - 1.20 |
| Open | 0.63 |
| Vol / Avg. | 17,046.00/150,426.00 |
| Mkt cap | 24.93M |
| P/E | - |
| Div/yield | - |
| EPS | -0.48 |
| Shares | 38.95M |
| Beta | 1.56 |
| Inst. own | 40% |
Events
May 14, 2013
Q3 2013 Palatin Technologies Earnings Conference Call -
Mar 18, 2013
Palatin Technologies at Roth Conference
Mar 5, 2013
Palatin Technologies at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -25547.10% | -23397.31% |
| Operating margin | -52450.46% | -25475.16% |
| EBITD margin | - | -24187.47% |
| Return on average assets | -19.69% | -129.95% |
| Return on average equity | -20.86% | -172.34% |
| Employees | 16 | - |
| Carbon Disclosure Rating | - | - |
Address
Cedar Brook Corporate Center 4B Cedar Brook Drive
CRANBURY, NJ 08512
United States - Map
+1-609-4952200 (Phone)
+1-609-4952201 (Fax)
CRANBURY, NJ 08512
United States - Map
+1-609-4952200 (Phone)
+1-609-4952201 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company engaged in the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems. As of June 30, 2010, the Company had three drug development programs, including Bremelanotide, Peptide melanocortin receptor agonists and PL-3994. Bremelanotide is a peptide melanocortin receptor agonist. PL-3994 is a peptide mimetic natriuretic peptide receptor A (NPR-A) agonist, for treatment of acute exacerbations of asthma, heart failure and refractory or difficult-to-control hypertension. The Company has licensed several families of melanocortin receptor-based compounds for treatment of obesity, diabetes and related metabolic syndrome to AstraZeneca AB (AstraZeneca).
Officers and directors
| John K. A. Prendergast Ph.D. | Chairman of the Board | |
| Carl Spana Ph.D. | President, Chief Executive Officer, Director | |
| Stephen T. Wills CPA | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary | |
| Robert K. deVeer Jr. | Independent Director | |
| Alan W. Dunton M.D. | Independent Director | |
| Zola P. Horovitz Ph.D. | Independent Director | |
| J. Stanley Hull | Independent Director | |
| Perry B. Molinoff M.D. | Independent Director |